First data from the FDA's new active surveillance programme highlight how the system might influence drug development programmes.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Unleashing the Mini-Sentinel. Nat Rev Drug Discov 11, 255–257 (2012). https://doi.org/10.1038/nrd3713
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3713
This article is cited by
-
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee
Nature Reviews Drug Discovery (2014)
